Agarwal Piyush K, Black Peter C, McConkey David J, Dinney Colin P N
Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.
Expert Opin Emerg Drugs. 2007 Sep;12(3):435-48. doi: 10.1517/14728214.12.3.435.
Although chemotherapy has improved the treatment of metastatic bladder cancer, resection and continual surveillance remain the modalities used for treatment of organ-confined disease. More targeted therapies are needed to address the shortcomings of existing treatments. The authors recently became aware of the overexpression of tyrosine kinase growth factor receptors in a variety of malignancies. These receptor tyrosine kinases are coupled to several proliferative and antiapoptotic pathways that drive cancer cell growth. Targeted small-molecule therapies, including monoclonal antibodies and tyrosine kinase inhibitors, directed at these receptors have proven effective against a variety of tumor models. In this report, the authors summarize the results of several such studies and discuss the rationale and potential use of novel targeted drugs in the treatment of bladder cancer.
尽管化疗改善了转移性膀胱癌的治疗，但手术切除和持续监测仍是治疗器官局限性疾病的常用方法。需要更多靶向治疗来弥补现有治疗方法的不足。作者最近意识到酪氨酸激酶生长因子受体在多种恶性肿瘤中过度表达。这些受体酪氨酸激酶与多种驱动癌细胞生长的增殖和抗凋亡途径相关联。针对这些受体的靶向小分子疗法，包括单克隆抗体和酪氨酸激酶抑制剂，已被证明对多种肿瘤模型有效。在本报告中，作者总结了几项此类研究的结果，并讨论了新型靶向药物治疗膀胱癌的理论依据和潜在用途。
